Uncategorized

Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome.

BioArctic AB’s partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

HUTCHMED Limited announces that it completed the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, for the treatment of refractory metastatic colorectal cancer.

Although telehealth use declined overall compared to the start of the COVID-19 pandemic, virtual visits still comprised the highest percentage of medical claim lines in 2021.

It’s the first time a naloxone-based therapy for opioid overdoses has been cleared for use without a prescription, potentially helping to improve access.

The bill mirrors California’s nurse staffing law which took effect in 2004 and outlines exactly how many patients a nurse in specific hospital units can care for at once.

Oak Street also announced on Thursday it’s canceling its annual board meeting following the CVS deal, which is expected to close in the first half of the year. Oak Street stockholders will meet on April 28 to vote on the sale.

Provider groups applauded the move, but said they’d need to see how the requirements are rolled back before passing judgment on whether the step would ease documentation burden on physicians.